Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals

• Authors: Jackson Mukonzo, Makerere University; Eleni Aklillu, Karolinska University Hospital; Vincent Marconi, Emory University; Raymond Schinazi, Emory University
• Journal Title: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
• Volume: Volume 83
• Publisher: ELSEVIER SCI LTD | 2019-06-01, Pages 98-101
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1016/j.ijid.2019.04.009
• Subjects: Biology, Virology; Chemistry, Pharmaceutical; Health Sciences, Public Health
• Keywords: Science & Technology; Life Sciences & Biomedicine; Infectious Diseases; MDR-TB; HIV; Treatment; Drug-drug interactions

Abstract

HIV-positive TB co-infected patients are at increased risk of multidrug-resistant (MDR)-TB compared to HIV-negative patients. Co-treatment of MDR-TB and HIV is common particularly in Sub-Saharan Africa where the co-morbidity is endemic. We discuss potential cellular metabolic pathway–mediated drug–drug interactions and the possible effect on HIV treatment outcomes of commonly prescribed antiretroviral therapy.